GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Journal article published in 2019 by
Adriano Venditti 
,
Alfonso Piciocchi ,
Anna Candoni,
Lorella Melillo,
Valeria Calafiore,
Roberto Cairoli,
Paolo de Fabritiis,
P. De Fabritiis,
Gabriella Storti,
Prassede Salutari,
Francesco Lanza,
Giovanni Martinelli,
Mario Luppi ,
Patrizio Mazza,
Maria Paola Martelli
and other authors.
,
Alfonso Piciocchi ,
Anna Candoni,
Lorella Melillo,
Valeria Calafiore,
Roberto Cairoli,
Paolo de Fabritiis,
P. De Fabritiis,
Gabriella Storti,
Prassede Salutari,
Francesco Lanza,
Giovanni Martinelli,
Mario Luppi ,
Patrizio Mazza,
Maria Paola Martelli
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points A risk-adapted, MRD-driven transplant strategy is a feasible approach for the treatment of younger adults with AML. Pretransplant MRD positivity should not contraindicate delivery of an allogeneic stem cell transplant.